1008769-87-6

Basic information

• Product Name: 4-bromo-3-(trifluoromethoxy)benzoic acid
• Synonyms: 4-bromo-3-(trifluoromethoxy)benzoic acid
• CAS NO: 1008769-87-6
• Molecular Weight: 285.017
• Mol File: 1008769-87-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-bromo-3-(trifluoromethoxy)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-bromo-3-(trifluoromethoxy)benzoic acid(1008769-87-6)
• EPA Substance Registry System: 4-bromo-3-(trifluoromethoxy)benzoic acid(1008769-87-6)

Safety Data

• Hazardous Substances Data: 1008769-87-6(Hazardous Substances Data)

Upstream product

• 1352621-29-4 ethyl 4-bromo-3-(trifluoromethoxy)benzoate 
• 1260742-02-6 ethyl 4-amino-3-(trifluoromethoxy)benzoate 
• 175278-22-5 4-amino-3-(trifluoromethoxy)benzoic acid 

Downstream Products

• 1352619-72-7 2-(4-fluorophenyl)-N-[4-(2-{[4-(morpholin-4-ylcarbonyl)-2-(trifluoromethoxy)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide 
• 1352621-31-8 [4-bromo-3-(trifluoromethoxy)phenyl](2-oxa-6-azaspiro[3.3]hept-6-yl)-methanone 
• 957206-36-9 4-bromo-3-trifluoromethoxy-benzoic acid methyl ester 
• 1403330-28-8 4-bromo-3-(trifluoromethoxy)benzamide 
• 1352621-30-7 [4-bromo-3-(trifluoromethoxy)phenyl](morpholin-4-yl)methanone 

Relevant articles and documents

FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS

Provided are fused tricyclic amide compounds, pharmaceutical compositions comprising at least one such fused tricyclic compound, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain tricyclic amide compounds that can be useful for inhibiting multiple (specifically BRAF and/or EGFR-T790M) kinases and for treating disorders mediated thereby.

SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to substituted triazolopyridine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as tumours and proliferative diseases, as well as to intermediate compounds useful in the preparation of said compounds.